Victory Capital Management Inc. Purchases 15,996 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Victory Capital Management Inc. raised its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 5.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 291,505 shares of the biopharmaceutical company’s stock after purchasing an additional 15,996 shares during the quarter. Victory Capital Management Inc. owned 0.25% of Catalyst Pharmaceuticals worth $5,795,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. GAMMA Investing LLC raised its holdings in shares of Catalyst Pharmaceuticals by 62.1% in the third quarter. GAMMA Investing LLC now owns 1,778 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 681 shares during the period. nVerses Capital LLC purchased a new stake in Catalyst Pharmaceuticals in the third quarter worth $50,000. CWM LLC lifted its position in shares of Catalyst Pharmaceuticals by 686.5% during the second quarter. CWM LLC now owns 4,066 shares of the biopharmaceutical company’s stock worth $63,000 after purchasing an additional 3,549 shares during the last quarter. Meeder Asset Management Inc. purchased a new stake in shares of Catalyst Pharmaceuticals during the second quarter valued at $70,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Catalyst Pharmaceuticals in the second quarter worth about $153,000. Institutional investors own 79.22% of the company’s stock.

Analyst Ratings Changes

CPRX has been the subject of several research reports. Stephens assumed coverage on shares of Catalyst Pharmaceuticals in a research report on Monday, November 18th. They issued an “overweight” rating and a $35.00 price objective for the company. StockNews.com upgraded Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, August 9th. HC Wainwright restated a “buy” rating and set a $30.00 price objective on shares of Catalyst Pharmaceuticals in a report on Friday, November 8th. Citigroup lifted their target price on Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the company a “buy” rating in a research report on Friday, August 9th. Finally, Truist Financial lifted their target price on Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the company a “buy” rating in a research report on Monday, November 11th. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Catalyst Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $31.14.

Catalyst Pharmaceuticals Trading Up 1.7 %

CPRX opened at $21.48 on Friday. The firm has a market cap of $2.56 billion, a price-to-earnings ratio of 17.95, a PEG ratio of 3.29 and a beta of 0.75. Catalyst Pharmaceuticals, Inc. has a 12 month low of $13.00 and a 12 month high of $24.27. The stock has a fifty day moving average price of $21.10 and a 200-day moving average price of $18.49.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.